Search sponsored by Coast Marketplace
Home Opinion Letters to the Editor

Letter: Making a difference

Terry Smith re diabetes

Published on October 6, 2017 12:01AM


Alfred Mann, who died in 2016, certainly made a difference. In his lifetime he founded Spectrolab, Helioteck, Pacesetter, Minimed, Bioness, Quallion and Mankind. All of his inventions benefited society. Minimed, which makes insulin pumps, was sold to Medtronic in 2001 for $4 billion. Alfred Mann also started Mankind, and put $1 billion of his own money into the business.

Diabetes is a terrible disease, which my wife and I have witnessed through our delivery of meals on wheels. In 2015 the FDA approved Mankind’s drug Alfrezza for inhaled insulin. There were conditions on the drug.

Today the FDA signed off on revised labeling for Alfrezza. The updated label includes study data that describe the time-action profile by dosage strength, showing the first measurable effect starts in 12 minutes, peaking at 35-40 minutes, then returning to baseline after 1.5 to 3 hours for the four unit and 12 unit cartridges, respectively. There is also an eight-unit cartridge.

Alfrezza is taken before meals. According to Mankind CEO Michael Castagna, many people with diabetes have a hard time maintaining the proper base of insulin. They are either too high or too low. Alfrezza will help maintain the proper dosage of insulin, and once taken is out of a person’s system in 1.5 to 3 hours according to the FDA label.

Terry J. Smith

Warrenton



Marketplace

Share and Discuss

Guidelines

User Comments